ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Private equity firm TPG invests in API maker Solara

by Rick Mullin
February 8, 2019 | APPEARED IN VOLUME 97, ISSUE 6

 

09706-buscon14-ibuprofen.jpg

An arm of the private equity firm TPG will invest $30 million in Solara Active Pharma, a maker of active pharmaceutical ingredients (APIs). Solara has five manufacturing sites and two research centers in India and is one of the world’s largest producers of ibuprofen. The deal marks TPG’s first investment in India’s life sciences sector. Solara was formed last year through the combination of the API businesses of Strides Shasun and Sequent Scientific, both of India.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment